Pirfenidone in Heart Failure with Preserved Ejection Fraction—Rationale and Design of the PIROUETTE Trial

Key Points

• To evaluate the efficacy of pirfenidone in treating heart failure with preserved ejection fraction.
• Randomized trial design
• Participants with heart failure and preserved ejection fraction
• Trial registered as NCT02932566
• Efficacy outcomes related to ejection fraction will be measured
• Potential benefits of pirfenidone will be assessed in the heart failure population